Apellis Pharmaceuticals, Inc. (APLS, Financial) has announced a significant addition to its Board of Directors with the appointment of Craig Wheeler. Wheeler, who brings over three decades of leadership expertise from the biopharmaceutical sector, will be joining the board effective immediately.
Craig Wheeler is the founder and chief executive officer of Headwaters Biotech Advisors, a firm that specializes in strategic consulting within the biotech industry. His extensive experience is expected to provide Apellis with valuable insights as the company continues to advance its mission of developing innovative treatments for patients suffering from various diseases.
This strategic move underscores Apellis's commitment to strengthening its leadership team with seasoned experts to navigate the complex biopharmaceutical landscape and drive the company’s growth forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $42.26 with a high estimate of $75.00 and a low estimate of $22.00. The average target implies an upside of 132.22% from the current price of $18.20. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $223.82, suggesting a upside of 1129.78% from the current price of $18.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
